A 9-Month-Old with Skeletal Abnormalities and a Consanguineous Sibling with Mucopolysaccharidosis IVA: The Role of Urinary Glycosaminoglycan Testing in Disease Diagnosis and Treatment Monitoring

Overview

Journal Clin Med Insights Case Rep

Publisher Sage Publications

Specialty General Medicine

Date 2021 Mar 22

PMID 33746520

Authors

Eric Goldman

Angela Vu

Kelly Dietz

Stefani N Thomas

Affiliations

Soon will be listed here.

Abstract

Mucopolysaccharidosis IVA (MPS IVA) is a rare autosomal recessive lysosomal storage disorder resulting from N-acetylgalactosamine-6-sulfatase (GALNS) deficiency that occurs in approximately 1 in 76 000 to 1 in 640 000 live births. Given that the diagnosis of MPS IVA relies heavily on the results of initial urine glycosaminoglycan (GAG) screening, cases that present with falsely normal urine GAG concentrations can delay the diagnosis and follow-up care for patients. This case study follows a patient diagnosed with MPS IVA at 9 months of age based on relation to a consanguineous 3-year-old sibling with MPS IVA and the use of direct enzyme activity analysis. Details regarding skeletal presentation and identification of genetic variants are presented along with data on follow-up urinary GAG monitoring during treatment with enzyme replacement therapy and treatment for a growth hormone disorder.

References

Nakamura-Utsunomiya A, Nakamae T, Kagawa R, Karakawa S, Sakata S, Sakura F . A Case Report of a Japanese Boy with Morquio A Syndrome: Effects of Enzyme Replacement Therapy Initiated at the Age of 24 Months. Int J Mol Sci. 2020; 21(3). PMC: 7037301. DOI: 10.3390/ijms21030989. View

Tomatsu S, Montano A, Oguma T, Dung V, Oikawa H, Carvalho T . Validation of keratan sulfate level in mucopolysaccharidosis type IVA by liquid chromatography-tandem mass spectrometry. J Inherit Metab Dis. 2010; 33 Suppl 3:S35-42. DOI: 10.1007/s10545-009-9013-x. View

Cattoni A, Motta S, Masera N, Gasperini S, Rovelli A, Parini R . The use of recombinant human growth hormone in patients with Mucopolysaccharidoses and growth hormone deficiency: a case series. Ital J Pediatr. 2019; 45(1):93. PMC: 6676577. DOI: 10.1186/s13052-019-0691-1. View

Wood T, Harvey K, Beck M, Burin M, Chien Y, Church H . Diagnosing mucopolysaccharidosis IVA. J Inherit Metab Dis. 2013; 36(2):293-307. PMC: 3590423. DOI: 10.1007/s10545-013-9587-1. View

Hendriksz C, Burton B, Fleming T, Harmatz P, Hughes D, Jones S . Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis. 2014; 37(6):979-90. PMC: 4206772. DOI: 10.1007/s10545-014-9715-6. View

Whitley C, Ridnour M, Draper K, Dutton C, Neglia J . Diagnostic test for mucopolysaccharidosis. I. Direct method for quantifying excessive urinary glycosaminoglycan excretion. Clin Chem. 1989; 35(3):374-9. View

Shimada T, Tomatsu S, Yasuda E, Mason R, Mackenzie W, Shibata Y . Chondroitin 6-Sulfate as a Novel Biomarker for Mucopolysaccharidosis IVA and VII. JIMD Rep. 2014; 16:15-24. PMC: 4221613. DOI: 10.1007/8904_2014_311. View

Saville J, McDermott B, Fuller M . Glycosaminoglycan fragments as a measure of disease burden in the mucopolysaccharidosis type I mouse. Mol Genet Metab. 2017; 123(2):112-117. DOI: 10.1016/j.ymgme.2017.12.007. View

Stone J . Urine analysis in the diagnosis of mucopolysaccharide disorders. Ann Clin Biochem. 1998; 35 ( Pt 2):207-25. DOI: 10.1177/000456329803500204. View

10.

Lin H, Lee C, Lo Y, Wang T, Huang S, Chen T . The relationships between urinary glycosaminoglycan levels and phenotypes of mucopolysaccharidoses. Mol Genet Genomic Med. 2018; 6(6):982-992. PMC: 6305646. DOI: 10.1002/mgg3.471. View

11.

Chistiakov D, Savostanov K, Kuzenkova L, Gevorkyan A, Pushkov A, Nikitin A . Molecular characteristics of patients with glycosaminoglycan storage disorders in Russia. Clin Chim Acta. 2014; 436:112-20. DOI: 10.1016/j.cca.2014.05.010. View

12.

Di Ferrante N . The measurement of urinary mucopolysaccharides. Anal Biochem. 1967; 21(1):98-106. DOI: 10.1016/0003-2697(67)90087-5. View

13.

Camelier M, Burin M, De Mari J, Vieira T, Marasca G, Giugliani R . Practical and reliable enzyme test for the detection of mucopolysaccharidosis IVA (Morquio Syndrome type A) in dried blood samples. Clin Chim Acta. 2011; 412(19-20):1805-8. DOI: 10.1016/j.cca.2011.06.001. View

14.

Bunge S, Kleijer W, Tylki-Szymanska A, Steglich C, Beck M, Tomatsu S . Identification of 31 novel mutations in the N-acetylgalactosamine-6-sulfatase gene reveals excessive allelic heterogeneity among patients with Morquio A syndrome. Hum Mutat. 1997; 10(3):223-32. DOI: 10.1002/(SICI)1098-1004(1997)10:3<223::AID-HUMU8>3.0.CO;2-J. View

15.

Lin H, Lo Y, Wang T, Huang S, Tu R, Chen T . Normalization of glycosaminoglycan-derived disaccharides detected by tandem mass spectrometry assay for the diagnosis of mucopolysaccharidosis. Sci Rep. 2019; 9(1):10755. PMC: 6656773. DOI: 10.1038/s41598-019-46829-x. View

16.

Piraud M, Maire I, Mathieu M . Pitfalls of screening for mucopolysaccharidoses by the dimethylmethylene blue test. Clin Chem. 1993; 39(1):163-4. View

17.

Dave M, Chawla P, Dherai A, Ashavaid T . Urinary Glycosaminoglycan Estimation as a Routine Clinical Service. Indian J Clin Biochem. 2015; 30(3):293-7. PMC: 4469061. DOI: 10.1007/s12291-014-0456-y. View

18.

Yabe H, Tanaka A, Chinen Y, Kato S, Sawamoto K, Yasuda E . Hematopoietic stem cell transplantation for Morquio A syndrome. Mol Genet Metab. 2015; 117(2):84-94. PMC: 5016080. DOI: 10.1016/j.ymgme.2015.09.011. View

19.

Bhattacharya K, Balasubramaniam S, Choy Y, Fietz M, Fu A, Jin D . Overcoming the barriers to diagnosis of Morquio A syndrome. Orphanet J Rare Dis. 2014; 9:192. PMC: 4279997. DOI: 10.1186/s13023-014-0192-7. View

20.

Dung V, Tomatsu S, Montano A, Gottesman G, Bober M, Mackenzie W . Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels. Mol Genet Metab. 2013; 110(1-2):129-38. PMC: 3779837. DOI: 10.1016/j.ymgme.2013.06.008. View